Untoward effects of chronic dual renin-angiotensin system blockade: Influence of previous chronic renal failure

International Journal of Clinical Practice

Volumn 60, Issue 9, 2006, Pages 1035-1039

  Robles, Nicolás Roberto ^a   Cancho, B ^a   Barroso, S ^a   Martin M V ^a   Sanchez Casado E ^a  

^a HOSPITAL INFANTA CRISTINA   (Spain)

Author keywords

Adverse effects; Dual blockade; Renin angiotensin system

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; IRBESARTAN; POTASSIUM ION;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DATA ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG SAFETY; ERYTHROPOIESIS; FEMALE; FOLLOW UP; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERKALEMIA; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STUDENT T TEST; SYSTOLIC BLOOD PRESSURE;

ANALYSIS OF VARIANCE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CREATININE; DRUG THERAPY, COMBINATION; FEMALE; HEMATOCRIT; HEMOGLOBINS; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POTASSIUM; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM;

EID: 33747177326     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.00995.x     Document Type: Article

References (35)

1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 11: 1456-62.
2. Mogensen CE, Keane, WF, Bennett, PH et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346: 1080-4.
3. Maschio G, Alberti D, Janin A et al. Effect of the angiotensin converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-45.
4. Kshirsagar AV, Joy MS, Hogan SL et al. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: A systematic overview of randomized placebo-controlled trials. Am J Kidney Dis 2000; 35: 695-707.
5. Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient level data. Ann Intern Med 2001; 135: 73-8.
6. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P for the Irbesartan in patients with type 2 diabetes and microalbuminuria study group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8.
7. Lewis E, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
8. Brenner BM, Cooper ME, De Zeeuw D et al. Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
9. Gruppo Italiano Studi Epidemiologici in Nefrologia (GISEN). Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk to terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-63.
10. Remuzzi A, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339: 1448-56.
11. Russo D, Minutolo R, Pisani A et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001; 38: 18-25.
12. Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 2000; 18: 89-95.
13. Luño J, Barrio V, Goicoechea MA et al. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies. Kidney Int 2002; 62 (Suppl. 82): S47-52.
14. Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 2002; 17: 1019-24.
15. Mogensen CE, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-4.
16. Nakao N, Yoshimura A, Morita M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 2003; 361: 117-24.
17. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med 1998; 158: 26-32.
18. Palmer FB. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004; 351: 585-92.
19. Mangrum AJ, Bakris GL. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: Safety issues. Semin Nephrol 2004; 24: 168-75.
20. Charytan C, Goldfarb-Rumyantzev A, Wang YF, Schwenk MH, Spinowitz BS. Effect of angiotensin-converting enzyme inhibitor of response to erythropoietin therapy in chronic dialysis patients. Am J Nephrol 1998; 18: 498-503.
21. Hirakata H, Onoyama K, Hori K, Fujishima M. Participation of the renin-angiotensin system in the captopril-induced worsening of anemia in chronic hemodialysis patients. Clin Nephrol 1986; 26: 27-32.
22. Walter J. Does captopril decrease the effect of human recombinant erythropoietin in hemodialysis patients? Nephrol Dial Transplant 1993; 8: 1428.
23. Robles NR, Angulo E, Grois J, Barquero A. Comparative effects of fosinopril and irbesartan on hematopoiesis in essential hypertensives. J Clin Basic Cardiol 2003; 6: 45-7.
24. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al. The Seventh Report of Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003; 289: 2560-72.
25. Ichikawa I. Will angiotensin II receptors blockers be renoprotectives in humans? Kidney Int 1996; 50: 684-92.
26. Brunner HR. ACE inhibitors in renal disease. Kidney Int 1992; 42: 463-79.
27. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-52.
28. Gould AB, Goodman S, DeWolf R, Onesti G, Swartz C. Interrelation of the renin-angiotensin system and erythropoietin in rats. J Lab Clin Med 1980; 96: 523-34.
29. Donnelly S, Shah BR. Erythropoietin deficiency in hyporeninemia. Am J Kidney Dis 1999; 33: 947-53.
30. Hortal L, Fernandez N, Vega N et al. Losartan versus ramipril in the treatment of postrenal transplant erythrocytosis. Transplant Proc 1998; 30: 2127-8.
31. Torregrosa JV, Campistol JM, Montesinos M, Rogado AG, Oppenheimer F, Andreu J. Efficacy of captopril on posttransplant erythrocytosis. Transplantation 1994; 58: 311-4.
32. Ferrari P, Marti HP, Pfister M, Frey FJ. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens 2002; 20: 125-31.
33. Kincaid-Smith P, Fairley K, Packham D. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal failure and proteinuria. Nephrol Dial Transplant 2002; 17: 597-601.
34. Berger ED, Bader BD, Ebert C, Risler T, Erley CM. Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition. J Hypertens 2002; 20: 739-43.
35. Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 2002; 62: 1020-5.